About MannKind Corp
MannKind Corp is a company based in Los Angeles (United States) founded in 1991. MannKind Corp has raised $50 million across 8 funding rounds from investors including Deerfield. The company has 407 employees as of December 31, 2024. MannKind Corp has completed 3 acquisitions, including Qrumpharma, V-Go and scPharmaceuticals. MannKind Corp offers products and services including Afrezza, V-Go, and Technosphere. MannKind Corp operates in a competitive market with competitors including NGM Biopharmaceuticals, Rhythm Pharmaceuticals, Impel NeuroPharma, Corcept and ViaCyte, among others.
- Headquarter Los Angeles, United States
- Employees 407 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mannkind Corporation
-
Annual Revenue
$285.5 M (USD)43.5as on Dec 31, 2024
-
Net Profit
$27.59 M (USD)0as on Dec 31, 2024
-
EBITDA
$77.65 M (USD)373.61as on Dec 31, 2024
-
Total Equity Funding
$50 M (USD)
in 8 rounds
-
Latest Funding Round
$200 M (USD), Post-IPO
Mar 01, 2021
- Investors
-
Employee Count
407
as on Dec 31, 2024
-
Investments & Acquisitions
Qrumpharma
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MannKind Corp
MannKind Corp is a publicly listed company on the NASDAQ with ticker symbol MNKD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of MannKind Corp
MannKind Corp offers a comprehensive portfolio of products and services, including Afrezza, V-Go, and Technosphere.
Inhaled insulin powder for managing diabetes effectively.
Patch device for continuous insulin administration.
Platform for delivering medications via inhalation.
People of MannKind Corp
Unlock access to complete
Unlock access to complete
Software Development Team
26 people
Leadership Team
20 people
Human Resources and Administration
9 people
Scientific Team
9 people
Board Team
8 people
Legal and Compliance
4 people
Sales and Marketing
3 people
System Team
2 people
Unlock access to complete
Funding Insights of MannKind Corp
MannKind Corp has successfully raised a total of $50M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MannKind Corp
MannKind Corp has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Deerfield.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked |
Investor details for MannKind Corp
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MannKind Corp
MannKind Corp has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Qrumpharma, V-Go and scPharmaceuticals.
Investment portfolio details for MannKind Corp
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for diabetes and respiratory disorders are developed.
|
Locked | Locked | 2014 | Locked | |
|
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure
|
Locked | Locked | 2013 | Locked | |
|
Product site of disposable, wearable insulin patch pump for continuous and bolus insulin
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for MannKind Corp
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - MannKind Corp
Detailed financials for MannKind Corp
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mannkind Corp Comparisons
Peer comparison for MannKind Corp
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MannKind Corp
MannKind Corp operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Rhythm Pharmaceuticals, Impel NeuroPharma, Corcept and ViaCyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Intranasal delivery technology for CNS diseases is developed.
|
|
| Locked | Locked | Locked |
Developer of cortisol modulators for the treatment of various diseases
|
|
| Locked | Locked | Locked |
Cell therapy for diabetes is developed from stem cells.
|
Detailed competitors of MannKind Corp
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mannkind Corp
Complete news archive for MannKind Corp
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MannKind Corp
MannKind Corp was founded in 1991 and raised its 1st funding round 13 years after it was founded.
MannKind Corp is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Michael Castagna is the current CEO of MannKind Corp.
MannKind Corp is a funded company, having raised a total of $50M across 8 funding rounds to date.
As of Dec 31, 2024, the latest employee count at MannKind Corp is 407.
Annual revenue of MannKind Corp is $285.5M as on Dec 31, 2024.
MannKind Corporation focuses on the discovery, development, and commercialization of a variety of therapeutic products through its proprietary drug delivery technology. The companys Technosphere formulation technology uses Technosphere Particles for pulmonary delivery of small molecules, peptides, and proteins directly by inhalation and thus helps in rapid drug absorption, bypassing the liver and also in enhancing bioavailability. The dry powder formulations are made with FDA approved excipients. The company also has proprietary products for inhalation profiling and single multi-use inhalers. The companys lead product includes Afrezza (inhalable ultra-rapid-acting insulin).
MannKind Corp's top competitors include Rhythm Pharmaceuticals, Corcept and NGM Biopharmaceuticals.
MannKind Corp offers Afrezza, V-Go, and Technosphere.
Yes, MannKind Corp is publicly traded on NASDAQ under the ticker symbol MNKD.
MannKind Corp has made 3 acquisitions, including Qrumpharma, V-Go, and scPharmaceuticals.
MannKind Corp has 1 investor. Key investors include Deerfield.
The ticker symbol of MannKind Corp is MNKD on NASDAQ.